Cereno Scientific Reports Positive Outcomes for CS1 in PAH After One Year of Treatment Cereno Scientific shares promising findings from its Expanded Access Program for CS1, validating safety and tolerability after 12 months in PAH patients.

Cereno Scientific Reports Positive Outcomes for CS1 in PAH After One Year of Treatment #Sweden #Gothenburg #Cereno_Scientific #PAH #CS1

Cereno Scientific's CS1 Treatment Shows Promising Safety Profile in PAH Patients Over a Year Cereno Scientific announces positive safety results for its CS1 treatment in PAH patients after a 12-month study, supporting its development as an oral therapy.

Cereno Scientific's CS1 Treatment Shows Promising Safety Profile in PAH Patients Over a Year #Sweden #Gothenburg #Cereno_Scientific #CS1_Treatment #PAH_Patients

Cereno Scientific Announces FDA-Approved Phase I PK Study of CS014 for PH-ILD Treatment Cereno Scientific has received approval to start a Phase I pharmacokinetic study for CS014, targeting pulmonary hypertension with innovative treatments aimed at enhancing patient life.

Cereno Scientific Announces FDA-Approved Phase I PK Study of CS014 for PH-ILD Treatment #Sweden #Gothenburg #PH-ILD #Cereno_Scientific #CS014

Cereno Scientific Launches Phase I Study of CS014 for PH-ILD Treatment After FDA Approval Cereno Scientific has been granted approval for a Phase I pharmacokinetic study of CS014, in a significant step toward treating pulmonary hypertension-related conditions.

Cereno Scientific Launches Phase I Study of CS014 for PH-ILD Treatment After FDA Approval #Sweden #Gothenburg #PH-ILD #Cereno_Scientific #CS014

Cereno Scientific Expands Development of CS014 to Target Pulmonary Hypertension in Lung Disease Cereno Scientific is broadening its clinical focus for CS014 to target pulmonary hypertension linked to interstitial lung disease, addressing significant unmet medical needs.

Cereno Scientific Expands Development of CS014 to Target Pulmonary Hypertension in Lung Disease #Sweden #Gothenburg #Pulmonary_Hypertension #Cereno_Scientific #CS014

Cereno Scientific Expands CS014 Focus to Treat Pulmonary Hypertension in Lung Disease Cereno Scientific is expanding the development of its treatment CS014 to address pulmonary hypertension related to interstitial lung disease, targeting a significant unmet medical need.

Cereno Scientific Expands CS014 Focus to Treat Pulmonary Hypertension in Lung Disease #Sweden #Gothenburg #PH-ILD #Cereno_Scientific #CS014

Cereno Scientific's Innovative HDAC Inhibitor CS014 Shows Promise in Cardiopulmonary Diseases Cereno Scientific has unveiled its groundbreaking HDAC inhibitor CS014, demonstrating effective antithrombotic properties without bleeding risks, supporting potential cardiovascular applications.

Cereno Scientific's Innovative HDAC Inhibitor CS014 Shows Promise in Cardiopulmonary Diseases #Sweden #Gothenburg #Cardiovascular_Diseases #Cereno_Scientific #CS014

Cereno Scientific Set to Participate in JPM Week 2026 and Biotech Showcase in San Francisco Cereno Scientific will be present at JPM Week and the Biotech Showcase in San Francisco from January 12-18, 2026, connecting with biotech leaders and investors.

Cereno Scientific Set to Participate in JPM Week 2026 and Biotech Showcase in San Francisco #United_States #San_Francisco #Biotech_Showcase #Cereno_Scientific #JPM_Week

Cereno Scientific Announces FDA Approval for CS1 Trial in PAH Patients Cereno Scientific has gained FDA clearance to start a Phase IIb trial for CS1, aiming to treat pulmonary arterial hypertension (PAH) and improve patient outcomes significantly.

Cereno Scientific Announces FDA Approval for CS1 Trial in PAH Patients #Gothenburg #USA #Cereno_Scientific #PAH #CS1

Cereno Scientific's CS1 Receives FDA Approval for Global Phase IIb Trial in PAH Indication Cereno Scientific celebrates FDA clearance to commence a Phase IIb trial for CS1, a potential treatment for pulmonary arterial hypertension. The trial aims to improve patient outcomes.

Cereno Scientific's CS1 Receives FDA Approval for Global Phase IIb Trial in PAH Indication #Gothenburg #Pulmonary_Hypertension #Cereno_Scientific #CS1

Cereno Scientific Advances Phase IIb Trial for CS1 Targeting Pulmonary Hypertension Cereno Scientific has submitted its trial protocol for CS1 to the FDA, a major step in developing new treatments for pulmonary arterial hypertension.

Cereno Scientific Advances Phase IIb Trial for CS1 Targeting Pulmonary Hypertension #Gothenburg #USA #Cereno_Scientific #PAH #CS1

Cereno Scientific Takes a Major Step in PAH Treatment Development by Submitting Phase IIb Trial Protocol to the FDA Cereno Scientific has submitted the protocol for its Phase IIb trial of CS1 to the FDA. This potential treatment for pulmonary arterial hypertension shows promise, aiming to change patient outcomes significantly.

Cereno Scientific Takes a Major Step in PAH Treatment Development by Submitting Phase IIb Trial Protocol to the FDA #Sweden #Gothenburg #Cereno_Scientific #PAH #CS1